AIkido Pharma Inc. (NASDAQ:AIKI – Get Rating) Director Kyle Michael Wool purchased 3,559 shares of the company’s stock in a transaction dated Friday, September 16th. The shares were acquired at an average price of $6.54 per share, for a total transaction of $23,275.86. Following the purchase, the director now directly owns 230,281 shares of the company’s stock, valued at approximately $1,506,037.74. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
AIkido Pharma Stock Performance
Shares of AIKI stock opened at $6.91 on Tuesday. AIkido Pharma Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $16.58. The firm has a market capitalization of $36.26 million, a price-to-earnings ratio of -2.55 and a beta of 1.33. The stock’s 50-day simple moving average is $6.08 and its 200-day simple moving average is $6.09.
Institutional Investors Weigh In On AIkido Pharma
A hedge fund recently raised its stake in AIkido Pharma stock. Jane Street Group LLC lifted its holdings in shares of AIkido Pharma Inc. (NASDAQ:AIKI – Get Rating) by 247.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 100,096 shares of the business services provider’s stock after acquiring an additional 71,284 shares during the period. Jane Street Group LLC owned approximately 0.11% of AIkido Pharma worth $45,000 at the end of the most recent quarter. 13.95% of the stock is currently owned by institutional investors.
About AIkido Pharma
AIkido Pharma Inc, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.
- Get a free copy of the StockNews.com research report on AIkido Pharma (AIKI)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for AIkido Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIkido Pharma and related companies with MarketBeat.com's FREE daily email newsletter.